查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933285

全球GLP-1受体激动剂市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

GLP-1 Receptor Agonist Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

GLP-1受体激动剂市场成长因子

受全球第2型糖尿病和肥胖症负担日益加重的推动，全球GLP-1受体激动剂市场正成为製药业成长最快的细分市场之一。 GLP-1受体激动剂是一类模拟天然存在的升糖素样胜肽-1激素作用的药物，有助于调节血糖、促进胰岛素分泌、抑制食慾和促进体重减轻。根据 Fortune Business Insights 预测，全球 GLP-1 受体激动剂市场规模预计在 2025 年达到 628.3 亿美元，并在 2026 年成长至 733.9 亿美元。预计到 2034 年，该市场规模将达到 2,541.9 亿美元，2026 年至 2034 年的复合年增长率 (CAGR) 高达 16.80%。北美地区在 2025 年将占市场主导地位，市场占有率达到 55.51%，这主要得益于该地区高昂的医疗保健支出和庞大的患者群体。 市场动态 市场驱动因素 2 型糖尿病和肥胖症盛行率的不断上升是 GLP-1 受体激动剂市场的主要驱动因素。根据国际糖尿病联盟 (IDF) 发布的 "糖尿病地图集" (2021)，2 型糖尿病影响着全球约 10.5% 的成年人口。世界卫生组织 (WHO) 的报告指出，自 1990 年以来，肥胖症的盛行率增加了一倍以上。 GLP-1 受体激动剂具有改善血糖控制和辅助减肥的双重功效，因此在治疗这两种疾病方面都非常有效。它们作为第一线或辅助疗法的应用日益广泛，尤其是在心血管风险患者中，这显着推动了市场需求。

市场限制因子

儘管需求强劲，但 GLP-1 受体激动剂的高昂价格仍然是一个主要限制因素。在美国，每月治疗费用可能接近 1000 美元，这限制了许多患者的用药。缺乏仿製药和复杂的生产流程也加剧了定价方面的挑战，并可能阻碍其广泛应用，尤其是在对成本敏感的地区。

市场机会

发展中国家为GLP-1受体激动剂生产商提供了巨大的未开发成长机会。未确诊糖尿病的高发生率、先进疗法的可近性有限以及不断完善的医疗基础设施，都创造了长期成长潜力。在这些地区推出价格合理的製剂并加强分销网络，可以显着扩大市场规模。

市场挑战

市场面临的主要挑战之一是GLP-1受体激动剂的短缺，这是由于全球对肥胖症和糖尿病治疗的需求激增所致。然而，製药公司正积极投资扩大产能，以应对供应限制。

市场趋势

影响市场的显着趋势之一是人工智慧（AI）与数位健康解决方案的融合。人工智慧驱动的工具正越来越多地被用于个人化治疗方案的选择、预测患者的反应以及改善治疗效果。此外，口服 GLP-1 製剂的研发势头强劲，与注射剂相比，口服製剂使用更方便，患者依从性也更高。

市场区隔分析

依药物类型划分，索玛鲁肽凭藉其在血糖控制和体重减轻方面的卓越疗效、获批多种适应症以及注射剂和口服剂型，占市场主导地位。其他药物，如艾塞那肽、利拉鲁肽、度拉鲁肽以及新兴的联合疗法，也正在推动市场扩张。

依年龄组划分，成人市场占最大占有率，这主要归因于第 2 型糖尿病和肥胖症的高发生率。然而，由于针对儿童患者的临床试验和监管批准的增加，预计儿童市场将以更快的速度成长。

依给药途径划分，注射用 GLP-1 疗法的广泛应用主导了肠外给药市场。然而，由于患者越来越倾向于非注射治疗，口服药物市场预计将快速成长。

依适应症划分，糖尿病仍然是主要市场，但由于核准药物的增加及其卓越的体重管理效果，肥胖症市场预计将在预测期内实现最高的复合年增长率。

区域洞察

北美预计将保持领先地位，在强劲的研发投入和高疾病盛行率的支撑下，2025年市场规模将达到348.8亿美元，2026年将达到407.4亿美元。欧洲由于众多大型製药公司的存在，占第二大市场。同时，由于肥胖率上升和医疗保健服务可近性的提高，亚太地区预计将经历快速成长。由于意识和基础设施的持续改善，拉丁美洲和中东及非洲地区具有长期成长潜力。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区主要适应症的流行情况（2025 年）
  • 主要公司产品线分析
  • 主要公司新产品发布
  • 主要产业趋势：併购、业务合作等等。
  • COVID-19 对市场的影响

第五章 全球 GLP-1 受体激动剂市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依药物类型划分
    • 索玛鲁肽
    • 艾塞那肽
    • 利西拉肽
    • 利拉鲁肽
    • 度拉鲁肽
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依年龄组别划分
    • 儿童
    • 成人
  • 市场分析、洞察与预测：依适应症
    • 糖尿病
    • 肥胖症
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美 GLP-1 受体激动剂市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲 GLP-1受体激动剂市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区 GLP-1 受体激动剂市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲 GLP-1 受体激动剂市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲 GLP-1 受体激动剂市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析(2025年)
  • 企业简介
    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • AstraZeneca
    • Pfizer, Inc.
    • Glenmark Pharmaceuticals Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: FBI112827

Growth Factors of GLP-1 receptor agonist Market

The global GLP-1 receptor agonist market has emerged as one of the fastest-growing segments within the pharmaceutical industry, driven by the rising burden of type 2 diabetes and obesity worldwide. GLP-1 receptor agonists are a class of drugs that mimic the action of the naturally occurring glucagon-like peptide-1 hormone, helping regulate blood glucose levels, stimulate insulin secretion, suppress appetite, and promote weight loss. According to Fortune Business Insights, the global GLP-1 receptor agonist market was valued at USD 62.83 billion in 2025, is projected to grow to USD 73.39 billion in 2026, and is expected to reach USD 254.19 billion by 2034, registering a strong CAGR of 16.80% during 2026-2034. North America dominated the market with a 55.51% share in 2025, supported by high healthcare spending and a large patient population.

Market Dynamics

Market Drivers

The increasing prevalence of type 2 diabetes and obesity is the primary driver of the GLP-1 receptor agonist market. As per the IDF Diabetes Atlas (2021), type 2 diabetes affects around 10.5% of the global adult population, while WHO reports indicate that obesity has more than doubled since 1990. GLP-1 receptor agonists offer dual benefits by improving glycemic control and supporting weight reduction, making them highly effective for managing both conditions. Their growing use as first-line or add-on therapies, particularly in patients with cardiovascular risk, is significantly boosting market demand.

Market Restraints

Despite strong demand, the high cost of GLP-1 receptor agonists remains a major restraint. In the U.S., monthly treatment costs can reach nearly USD 1,000, limiting accessibility for many patients. The lack of generic alternatives and complex manufacturing processes further contribute to pricing challenges, which may restrict broader adoption, especially in cost-sensitive regions.

Market Opportunities

Developing countries present significant unmet opportunities for GLP-1 receptor agonist manufacturers. High rates of undiagnosed diabetes, limited access to advanced therapies, and expanding healthcare infrastructure create long-term growth potential. Introducing affordable formulations and strengthening distribution networks in these regions could substantially expand the market footprint.

Market Challenges

A key challenge faced by the market is the shortage of GLP-1 receptor agonist drugs, driven by overwhelming global demand for obesity and diabetes treatment. However, pharmaceutical companies are actively investing in manufacturing capacity expansion to address supply constraints.

Market Trends

One of the prominent trends shaping the market is the integration of artificial intelligence (AI) and digital health solutions. AI-driven tools are increasingly being used to personalize treatment selection, predict patient response, and improve therapy outcomes. Additionally, the development of oral GLP-1 formulations is gaining momentum, offering improved convenience and patient compliance compared to injectable options.

Segmentation Analysis

By drug type, semaglutide dominates the market due to its superior efficacy in glycemic control and weight loss, approval for multiple indications, and availability in both injectable and oral forms. Other drugs such as exenatide, liraglutide, dulaglutide, and emerging combination therapies also contribute to market expansion.

By age group, the adult segment holds the largest share owing to the high prevalence of type 2 diabetes and obesity. However, the pediatric segment is expected to grow at a faster rate due to increasing clinical trials and regulatory approvals for younger populations.

By route of administration, the parenteral segment dominates due to the widespread use of injectable GLP-1 therapies, while the oral segment is expected to grow rapidly with rising patient preference for non-injectable treatments.

By indication, diabetes remains the dominant segment, while the obesity segment is projected to grow at the highest CAGR during the forecast period due to increasing approvals and strong weight-management outcomes.

Regional Insights

North America led the market with a valuation of USD 34.88 billion in 2025 and USD 40.74 billion in 2026, driven by strong R&D investments and high disease prevalence. Europe holds the second-largest share due to the presence of major pharmaceutical players, while Asia Pacific is expected to witness rapid growth supported by rising obesity rates and improving healthcare access. Latin America and the Middle East & Africa offer long-term growth potential as awareness and infrastructure continue to improve.

Competitive Landscape

The market is highly consolidated, with Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, and Sanofi holding significant shares. Strong product portfolios, regulatory approvals, strategic collaborations, and manufacturing expansions are key strategies adopted by these players to maintain their competitive positions.

Conclusion

The global GLP-1 receptor agonist market is set for exceptional growth, expanding from USD 62.83 billion in 2025 to USD 254.19 billion by 2034. Rising diabetes and obesity prevalence, expanding therapeutic applications, and continuous innovation in drug formulations are driving market momentum. While high costs and supply challenges remain, increasing investments, technological integration, and expanding access in emerging markets are expected to sustain strong long-term growth for the GLP-1 receptor agonist market.

Segmentation By Drug

  • Semaglutide
  • Exenatide
  • Lixisenatide
  • Liraglutide
  • Dulaglutide
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adults

By Indication

  • Diabetes
  • Obesity
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Indications, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Semaglutide
    • 5.1.2. Exenatide
    • 5.1.3. Lixisenatide
    • 5.1.4. Liraglutide
    • 5.1.5. Dulaglutide
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Indication
    • 5.4.1. Diabetes
    • 5.4.2. Obesity
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Semaglutide
    • 6.1.2. Exenatide
    • 6.1.3. Lixisenatide
    • 6.1.4. Liraglutide
    • 6.1.5. Dulaglutide
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Indication
    • 6.4.1. Diabetes
    • 6.4.2. Obesity
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Semaglutide
    • 7.1.2. Exenatide
    • 7.1.3. Lixisenatide
    • 7.1.4. Liraglutide
    • 7.1.5. Dulaglutide
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Indication
    • 7.4.1. Diabetes
    • 7.4.2. Obesity
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Semaglutide
    • 8.1.2. Exenatide
    • 8.1.3. Lixisenatide
    • 8.1.4. Liraglutide
    • 8.1.5. Dulaglutide
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Indication
    • 8.4.1. Diabetes
    • 8.4.2. Obesity
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Semaglutide
    • 9.1.2. Exenatide
    • 9.1.3. Lixisenatide
    • 9.1.4. Liraglutide
    • 9.1.5. Dulaglutide
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Indication
    • 9.4.1. Diabetes
    • 9.4.2. Obesity
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Semaglutide
    • 10.1.2. Exenatide
    • 10.1.3. Lixisenatide
    • 10.1.4. Liraglutide
    • 10.1.5. Dulaglutide
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Indication
    • 10.4.1. Diabetes
    • 10.4.2. Obesity
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Eli Lilly and Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Novo Nordisk A/S
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AstraZeneca
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Glenmark Pharmaceuticals Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Teva Pharmaceutical Industries Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 2: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 4: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 5: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 8: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 10: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 14: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 16: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 17: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 20: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 22: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 23: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 26: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 28: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 32: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 34: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 35: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global GLP-1 Receptor Agonists Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025 & 2034
  • Figure 3: Global GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025 & 2034
  • Figure 6: Global GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global GLP-1 Receptor Agonists Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 9: North America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 10: North America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 13: North America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 14: North America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 15: North America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 16: North America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America GLP-1 Receptor Agonists Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America GLP-1 Receptor Agonists Market Value Share (%), By Country, 2025
  • Figure 20: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 21: Europe GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 22: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Europe GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 26: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 27: Europe GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 28: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 33: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 34: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion),by Age Group, 2025 & 2034
  • Figure 37: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 38: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 39: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 40: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 45: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 46: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 49: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 50: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 51: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 52: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 57: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 58: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 61: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 62: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 63: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 64: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global GLP-1 Receptor Agonists Market Share (%), By Company, 2025